The Department of Health and Human Services, Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA), Silver Spring, Maryland, is actively recruiting physicians specialized in Radiation Oncologists and other physicians with expertise in theragnostics and medical countermeasures to serve in a dynamic, highly challenging and innovative atmosphere at the intersection of law, medicine, and science. Medical Officers are the cornerstone of FDA's mission to ensure the safety and efficacy of drug products. As a medical officer, you will have the opportunity to:
Advance the public health through new drug development.
Experience teaching and training opportunities.
Interact with pharmaceutical companies and develop health policy.
Work with a wide range of scientific disciplines in a team oriented atmosphere.
SALARY & BENEFITS
Civil service base salary at the GS-14 level, plus a generous supplemental allowance determined by relevant experience, medical specialty, and board certification.
Excellent Federal Government benefits package (health insurance, life insurance, retirement, etc.).
Relocation expenses and student loan repayment may be paid to eligible candidates.
Optional weekly professional development time in order to maintain clinical skills.
Flexible and/or home-based work schedules available.
Applicants must have a Doctor of Medicine or Doctor of Osteopathy degree from an accredited medical school. Graduates of foreign medical schools must be certified by the Education Commission for Foreign Medical Graduates (ECFMG). Candidates for Civil Service or U.S. Commissioned Corps must be U.S. citizens. Permanent U.S. residents may apply for staff fellowship appointments. Certification by the American Board of Radiology (ABR) is required.
If you have any questions, you may direct them to the Recruitment Team at email@example.com or (301) 796-0800. Those who wish to apply should submit their cover letters and CV/resumes to OND-Employment@fda.hhs.gov. Please indicate that you are applying to source code #018-009EG.
Internal Number: 18-009EG
About FDA's Office of New Drugs
The Center for Drug Evaluation & Research (CDER) at the Food and Drug Administration (FDA) carries out an essential public health mission by ensuring that safe and effective drugs are available to improve the health of the American people.
The Office of New Drugs in CDER is the nexus where this oversight of drug development and review takes place. We advance public health by helping to bring new product innovations to market. Our work begins when pharmaceutical manufacturers prepare to begin clinical testing of their new products. We ensure the safety of patients in clinical trials and provide advice to manufacturers on the design and conduct of the trial and the analysis of the trial results. Our work continues when development of the product is complete and the manufacturer seeks approval to market the product. We evaluate and analyze the evidence of the drug’s safety and effectiveness to determine whether the new product meets FDA’s standards for approval. As part of this review, we also play a critical role in ensuring that healthcare professionals and patients have accurate science-based information so that new drugs are used safely and appropriately. Following approval, w...e continue to monitor marketed products to ensure their continued safety as they are used in a broader patient population.
Our work in OND impacts the lives of Americans on a daily basis. We rely on experienced physicians and other highly qualified and dedicated professionals to carry out our important mission. OND operates in a team-based, collegial environment where our staff interacts with various scientific disciplines (e.g., statistics, clinical pharmacology, chemistry) that are all involved in drug regulation. Many opportunities also exist to provide scientific leadership through collaborative work with the pharmaceutical industry, academia, and other domestic and foreign regulatory agencies and other organizations. With the increasingly rapid development of new therapies that improve the lives of patients here and abroad, this is an exciting time to be part of the drug development and review enterprise.